Ketojenik Diyetin Beyin Tümörleri Tedavisinde Kullanımı

Authors

Serdar Pekuz
Aycan Ünalp
Akademisyen Yayınevi
https://orcid.org/0000-0002-3611-5059

Synopsis

Primary brain tumors (PBT) have a high malignancy rate and poor prognosis, particularly in childhood, with Glioblastoma multiforme (GBM) being the most common malignant tumor in this group. Despite standard multidisciplinary treatment approaches including surgical resection, radiotherapy, and chemotherapy, the average overall survival time remains less than two years, necessitating the exploration of alternative and complementary therapeutic options that could improve patient prognosis. In this context, the ketogenic diet (KD)—which induces endogenous ketone production through high fat, adequate protein, and low carbohydrate content—attracts attention in neuro-oncology in addition to its long-standing use in refractory epilepsy. Brain tumors, which rely heavily on the glycolytic pathway due to reduced expression of ketolytic enzymes in tumor cells and the Warburg effect, undergo energy restriction in the low-carbohydrate environment provided by the KD. Reduced blood glucose and ketone body formation resulting from KD offer protection against oxidative stress via β-hydroxybutyrate, suppress markers of angiogenesis and peritumoral edema in tumor tissue, and demonstrate potential to extend survival when combined with radiotherapy. Clinical and case studies have indicated that KD reduces tumor glucose metabolism, decreases seizure frequency, and can be administered safely without severe side effects. However, due to compliance challenges stemming from unpalatability, as well as a lack of standardization regarding diet type, initiation timing, and target ketosis levels, high-quality randomized controlled trials are required to establish the definitive efficacy of KD in PBT treatment.

References

Ostrom QT, Patil N, Cioffi G, ve ark. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol 2020; 22:iv1.

Nabors LB, Portnow J, Ammirati M, ve ark. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15(11):1331-1345.

Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010;67(3):279-283.

Panhans CM, Gresham G, Amaral LJ, Hu J. Exploring the Feasibility and Effects of a Ketogenic Diet in Patients With CNS Malignancies: A Retrospective Case Series [published correction appears in Front Neurosci. 2020 Jun 25;14:661]. Front Neurosci. 2020;14:390.

Mauer GD, Brucker DP, Bahr O ve ark. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer (2011) 11:315.

Chang HT, Olson LK, Schwarz KA. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet. Nutr Metab (2013) 10:47.

Warburg O. On the origin of cancer cells. Science 123, (1956a). 309–314. 10.1126/science.123.3191.30

Arismendi-Morillo GJ, Castellano-Ramirez AV Ultrastructural mitochondrial pathology in human astrocytic tumors: potentials implications pro-therapeutics strategies. J Electron Microsc 2008 (Tokyo) 57:33–39

Deighton RF, Le Bihan T, Martin SF ve ark. Interactions among mitochondrial proteins altered in glioblastoma. J Neurooncol (2014) 118:247–256

Arismendi-Morillo G, Castellano-Ramirez A, Seyfried TN. Ultrastructural characterization of the Mitochondria associated membranes abnormalities in human astrocytomas: functional and therapeutics implications. Ultrastruct Pathol (2017) 41:234–244

Kiebish MA, Han X, Cheng H, Chuang JH, Seyfried TN. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J Lipid Res (2008) 49:2545–2556

Shimazu T, Hirschey MD, Newman J ve ark. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science (2013) 339(6116):211–4.

Woolf EC, Curley KL, Qingwei L ve ark. The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis. Invasive potential and vascular permeability in a mouse glioma model. PLoS One (2015) 10(6):e0130357.

Abdelwahab M, Fenton K, Preul M ve ark. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One (2012) 7:e36197.

Adeberg S, Bernhardt D, Foerster R ve ark. The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. 2015 ActaOncol., 1–7

Nebeling L.C., Miraldi F., Shurin S.B., Lerner E. Effects of a ketogenic diet ontumor metabolism and nutritional status in pediatric oncology patients: two case reports. 1995 J. Am. Coll. Nutr. 14 (2), 202–208.

van der Louw EJTM, Reddingius RE, Olieman JF, Neuteboom RF, Catsman-Berrevoets CE. Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study. Pediatr Blood Cancer. 2019 Mar;66(3): e27561. Epub 2018 Nov 28

Schwartz K, Chang HT, Nikolai M ve ark. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab. 2015;3:3. Published 2015 Mar 25.

Winter SF, Loebel F, Dietrich J. Role of ketogenic metabolic therapy in malignant glioma: a systematic review. Crit Rev Oncol Hematol (2017) 112:41–58.

Schwartz KA, Noel M, Nikolai M, Chang HT. Investigating the Ketogenic Diet As Treatment for Primary Aggressive Brain Cancer: Challenges and Lessons Learned. Front Nutr. 2018 Feb 23;5:11. PMID: 29536011; PMCID: PMC5834833.

Rieger J, Bahr O, Maurer GD ve ark. ERCO A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44:1843–52.

Published

September 30, 2021

License

License